Servier has announced plans to present nine scientific abstracts, including five oral presentations, at the Society for Neuro-Oncology Annual Meeting in Philadelphia from 12 to 15 November 2026, highlighting new evidence across its Voranigo and Ojemda glioma portfolio. The programme includes extended follow-up from the Phase 3 INDIGO and Phase 2 FIREFLY-1 trials, alongside observational analyses exploring treatment outcomes in additional patient populations.
The announcement comes as the foundation-governed pharmaceutical group expands its position in targeted brain cancer therapies following its approximately US$2.5 billion acquisition of Day One Biopharmaceuticals in April 2026. That transaction added Ojemda, an established US treatment for certain relapsed or refractory paediatric low-grade gliomas, to a portfolio already anchored by Voranigo for selected IDH-mutant Grade 2 gliomas.
The forthcoming presentations address different clinical and commercial questions. For Voranigo, the focus is shifting towards long-term disease control, seizures, quality of life and evidence from routine practice. For Ojemda, updated four-year follow-up will examine response durability, periods without treatment and outcomes after retreatment in children with BRAF-altered low-grade glioma.
The distinction between approved indications and emerging research is particularly important. Both medicines are already authorised in the United States for defined patient populations, but some analyses scheduled for SNO 2026 concern treatment experiences outside those populations or clinical questions not established by the original pivotal trials.
What will Servier’s nine SNO 2026 abstracts reveal about its expanding glioma treatment portfolio?
Servier’s conference programme combines results from randomised clinical research, longer-term follow-up and retrospective observational studies. Five of the nine abstracts are scheduled for oral presentation, reflecting the company’s emphasis on generating additional evidence for established therapies rather than relying exclusively on new drug candidates. The breadth of the programme also illustrates how glioma development increasingly depends on molecular tumour classification.
Voranigo, the brand name for vorasidenib, is an oral inhibitor of mutant isocitrate dehydrogenase 1 and 2 enzymes. It received United States Food and Drug Administration approval in August 2024 for patients aged 12 years and older with Grade 2 astrocytoma or oligodendroglioma carrying a susceptible IDH1 or IDH2 mutation, following surgery. The authorisation includes patients who have undergone biopsy, subtotal resection or gross total resection.
Ojemda, the brand name for tovorafenib, is an oral RAF kinase inhibitor that received accelerated FDA approval in April 2024. Its approved indication covers patients aged six months and older with relapsed or refractory paediatric low-grade glioma harbouring a BRAF fusion, rearrangement or BRAF V600 mutation. Unlike Voranigo, which is administered daily, Ojemda follows a once-weekly treatment schedule.
These medicines are not interchangeable therapies for a common patient population. Their molecular targets, disease settings, clinical evidence and regulatory pathways differ substantially. Servier’s portfolio strategy is therefore centred on addressing distinct subsets of glioma through molecularly targeted treatments.
The clinical importance of this approach lies in the heterogeneous nature of gliomas. Tumours with different molecular alterations can behave differently, respond to different therapies and require different treatment strategies. Accurate molecular diagnosis is consequently essential to identifying the populations addressed by each medicine.
The November conference will offer an opportunity to assess how the existing evidence base is developing. However, the 6 November announcement is a preview of presentations scheduled for the following week, not confirmation that all newly described findings have undergone full peer-reviewed publication.
How does the extended Phase 3 INDIGO follow-up strengthen the evidence supporting Voranigo?
The Phase 3 INDIGO trial provides the principal randomised evidence supporting Voranigo’s approval. The multinational, double-blind, placebo-controlled study enrolled 331 patients with Grade 2 IDH-mutant astrocytoma or oligodendroglioma who had undergone surgery but had not received chemotherapy or radiotherapy. Participants were assigned to vorasidenib or placebo, with progression-free survival assessed through blinded independent central review.
The original pivotal analysis established a statistically significant benefit in progression-free survival. Median progression-free survival was 27.7 months with vorasidenib compared with 11.1 months with placebo, corresponding to a hazard ratio of 0.39. The trial also demonstrated a statistically significant improvement in time to next intervention, an important outcome in patients for whom delaying additional treatment may carry meaningful clinical value.
Longer follow-up has provided a more developed assessment of the treatment effect. At the 2026 American Society of Clinical Oncology Annual Meeting, Servier reported a median progression-free survival of 44.1 months by blinded independent review among patients initially assigned to Voranigo. The analysis was based on a January 2025 data cutoff and a median follow-up of 41.6 months.
Servier’s SNO 2026 programme includes additional analyses examining outcomes across histological subtypes and prognostic characteristics. These may help clinicians better understand whether the treatment effect appears consistent across clinically relevant subsets of the trial population. Nevertheless, subgroup findings must be interpreted in relation to their statistical design, sample sizes and whether the comparisons were prespecified.
The longer-term analysis also requires attention to the trial’s crossover arrangements. Patients initially receiving placebo were permitted to receive vorasidenib after progression, and the study was subsequently unblinded. As a result, extended outcomes cannot be interpreted in exactly the same way as the original blinded randomised comparison.
The accumulated evidence supports continued evaluation of long-term disease control, but it does not establish an overall survival advantage. Survival outcomes may require substantially longer follow-up, and crossover can complicate the interpretation of treatment differences. For a disease that may follow a prolonged clinical course, progression-free survival and the timing of subsequent interventions remain important measures, but they are not substitutes for every patient-centred outcome.
Could the new seizure and quality-of-life analyses change how clinicians assess Voranigo’s long-term value?
Beyond radiographic progression, the INDIGO programme is generating evidence on outcomes that can affect daily life for patients with low-grade glioma. Servier plans to present an analysis examining seizure activity and changes in quality of life during longer-term Voranigo treatment. These outcomes are clinically relevant because patients may live with the effects of their disease for many years.
Seizures are a common and potentially burdensome manifestation of diffuse glioma. They can affect employment, education, independence and other aspects of daily functioning, while their management may require additional medication. A treatment associated with improved seizure control could therefore offer value beyond delaying measurable tumour progression, provided the relationship is established through reliable analysis.
Earlier Servier disclosures from the 2026 INDIGO follow-up reported a 72% reduction in the rate of on-treatment seizures among Voranigo-treated patients. The forthcoming SNO analysis is expected to provide further information on sustained seizure activity and delayed worsening of quality of life. These are promising observations, although the extent to which they establish an independent treatment effect depends on the assessment methods and statistical interpretation.
Seizure frequency can also be influenced by baseline disease characteristics, antiseizure medications, reporting methods and changes in tumour burden. Quality-of-life measurements introduce additional considerations, including missing assessments and differences between patients who remain on treatment and those who discontinue. Consequently, favourable trends require careful examination before being treated as definitive evidence of broader functional benefit.
The safety profile is equally important when evaluating prolonged use. Voranigo is associated with clinically relevant liver enzyme elevations, and its prescribing information includes monitoring requirements and warnings concerning reproductive risks and potential effects on fertility. Longer exposure therefore involves a balance between maintaining disease control and managing treatment-related toxicity.
Servier previously reported that fewer than 5% of Voranigo-treated patients discontinued therapy because of adverse events in the extended INDIGO analysis. That finding provides context for treatment persistence but does not remove the need to evaluate individual adverse events, dose modifications or the consequences of longer-term exposure. Updated safety information remains particularly relevant as treatment duration extends beyond the period available at initial approval.
What do the 499-patient Grade 2 and 80-patient Grade 3 real-world analyses mean for Voranigo?
Two scheduled SNO presentations will examine retrospective observational data involving Voranigo use outside the controlled environment of INDIGO. One analysis includes 499 patients with Grade 2 IDH-mutant glioma and evaluates time to next intervention. The other examines a cohort of 80 patients with Grade 3 IDH-mutant glioma, a population outside Voranigo’s currently approved US indication.
Real-world evidence can provide important information about treatment patterns, patient selection and outcomes in clinical practice. Randomised trials typically apply defined eligibility criteria that may exclude patients with more complicated treatment histories or additional clinical conditions. Observational studies may therefore help identify how medicines are being used across a broader range of patients.
For the Grade 2 cohort, Servier has indicated that its analysis suggests short-term real-world effectiveness, with the most favourable results observed among patients receiving Voranigo as an initial treatment. However, time to next intervention can be influenced by factors beyond the medicine itself, including physician treatment preferences, tumour characteristics, imaging frequency and access to subsequent therapy.
The non-randomised design creates additional uncertainty when comparing treatment sequences. Patients receiving Voranigo earlier may differ systematically from those treated after other interventions, potentially affecting outcomes independently of the drug. Appropriate adjustment can reduce some biases, but retrospective analysis cannot necessarily eliminate unmeasured confounding.
The Grade 3 cohort is particularly relevant to Servier’s longer-term development strategy because it examines a population beyond the established US label. However, the inclusion of 80 patients in an observational analysis does not establish efficacy in Grade 3 disease or constitute regulatory approval for that use. Differences in tumour biology, previous treatment, disease aggressiveness and clinical endpoints would need to be considered before drawing broader conclusions.
Any extension of Voranigo’s approved indication would require an appropriate evidence package and regulatory assessment. The commercial opportunity associated with broader use should therefore remain separate from the existing authorised market. The November data may help refine future research priorities, but cannot by themselves establish a new treatment standard.
What could the four-year FIREFLY-1 analysis reveal about Ojemda treatment durability and retreatment?
Ojemda’s four-year FIREFLY-1 follow-up is among the most important elements of Servier’s paediatric glioma programme. The Phase 2 trial evaluated tovorafenib in patients with relapsed or refractory BRAF-altered paediatric low-grade glioma, with the pivotal efficacy population comprising 76 patients. Unlike INDIGO, FIREFLY-1 was an open-label, single-arm study without a randomised comparison against another treatment.
The FDA granted accelerated approval based on response rate and duration-of-response evidence from the study. At the original regulatory assessment, the FDA reported an overall response rate of 51% under the specified independent review criteria. The single-arm design established evidence of antitumour activity but did not independently quantify comparative benefit against chemotherapy or another targeted treatment.
Subsequent follow-up has provided additional information on treatment duration and outcomes after patients stop therapy. At the 2025 Society for Neuro-Oncology meeting, Day One Biopharmaceuticals reported three-year follow-up showing a 53% overall response rate among 76 evaluable patients and a median duration of response of 19.4 months. The company also reported a median time to next treatment of 42.6 months.
Among 39 patients entering a treatment-free observation period, 30 remained without additional treatment for at least 12 months. These results suggested that some patients could experience meaningful intervals without ongoing therapy, although their interpretation was limited by the non-randomised design and selected population entering observation.
The earlier analysis also included eight patients who received Ojemda again following subsequent disease progression. Day One reported an average maximum tumour reduction of approximately 38% during retreatment, with a median follow-up of nine months. The small cohort made the findings exploratory rather than definitive evidence of retreatment effectiveness.
Servier’s forthcoming four-year analysis is expected to provide further information about post-treatment observation, disease progression and retreatment outcomes. The 6 November announcement did not disclose a complete new numerical dataset for these endpoints, so the previously reported three-year findings should not be presented as the results of the upcoming analysis.
Longer-term evidence is particularly relevant in paediatric low-grade glioma because patients may require several treatment courses over childhood and adolescence. The clinical objective often extends beyond immediate tumour shrinkage to preserving neurological function, managing treatment toxicity and limiting the cumulative burden of interventions. Understanding when treatment can be interrupted and whether it can be restarted successfully may eventually inform more individualised treatment strategies.
Why does Ojemda’s accelerated approval make FIREFLY-2 an important regulatory milestone?
Ojemda’s existing US indication was granted under the FDA’s accelerated approval pathway, which permits authorisation based on evidence reasonably likely to predict clinical benefit in serious diseases. Continued approval may depend on the verification and description of that benefit through appropriate confirmatory evidence. For Ojemda, the ongoing FIREFLY-2 programme is therefore central to the longer-term regulatory strategy.
FIREFLY-2 is a global, randomised, open-label Phase 3 trial evaluating tovorafenib against standard-of-care chemotherapy in patients with RAF-altered paediatric low-grade glioma requiring first-line systemic therapy. The trial completed enrolment in May 2026, with approximately 400 participants across around 140 clinical sites. Its primary endpoint includes overall response assessment, with additional outcomes examining progression, treatment durability and subsequent interventions.
This trial addresses a materially different question from the original FIREFLY-1 study. Rather than examining activity in previously treated disease through a single-arm design, FIREFLY-2 directly compares tovorafenib with chemotherapy in an earlier treatment setting. Such comparative evidence may help clarify the treatment’s relative clinical value and support regulatory decisions concerning its potential use before relapse.
At the May 2026 enrolment announcement, Servier expected preliminary results during 2027. That timeline remains a development expectation rather than an established clinical result. The outcome will depend on the observed efficacy, safety and statistical performance against the trial’s prespecified endpoints.
Long-term safety will also remain central to regulatory and clinical assessment. Ojemda’s prescribing information includes warnings concerning haemorrhage, skin reactions, liver toxicity and effects on growth in children. These considerations become particularly important when treatment may be administered during periods of active physical development.
The FIREFLY-1 follow-up can help characterise response durability and treatment experience, but it cannot replace the comparative evidence being generated by FIREFLY-2. The two studies serve complementary purposes within the development programme, with the confirmatory trial carrying greater weight for establishing comparative outcomes and potentially supporting broader authorisation.
How has the US$2.5 billion Day One acquisition changed Servier’s neuro-oncology business?
Servier completed its acquisition of Day One Biopharmaceuticals in April 2026 through a transaction valued at approximately US$2.5 billion in equity. The acquisition brought Ojemda, its established US commercial operations and additional clinical development programmes into the group. It also strengthened Servier’s position in rare oncology indications alongside its existing IDH-mutant glioma franchise.
The transaction was commercially meaningful because Ojemda had already developed a revenue base before the acquisition. Day One reported US$155.4 million in net Ojemda product revenue for 2025, representing substantial growth from its initial launch year. Those sales provide evidence of an established commercial franchise, although historical performance does not establish the medicine’s future growth trajectory under Servier’s ownership.
Servier had separately reported group revenue of €6.86 billion for the financial year ended September 2025, including approximately €2.21 billion from oncology. The company identified the US launch of Voranigo as a significant contributor to oncology growth during that period. Those results predated the Day One acquisition and therefore should not be treated as including a full-year contribution from Ojemda.
Together, the two medicines give Servier marketed assets addressing distinct molecularly defined glioma populations. The commercial strategy involves sustaining uptake in approved settings while generating evidence that could support greater clinical utility or future label expansion. However, opportunities in additional populations remain dependent on regulatory decisions and appropriate clinical evidence.
The acquisition also introduces geographical considerations. Day One licensed ex-US rights to Ojemda to Ipsen, meaning Servier’s direct commercial rights and responsibilities differ by market. The group’s ability to expand international availability will consequently depend on existing licensing arrangements and jurisdiction-specific regulatory decisions.
Servier’s foundation-governed ownership structure also distinguishes it from publicly traded biotechnology companies whose valuations may react directly to individual conference abstracts. Day One’s shares ceased trading following the acquisition, and its former Nasdaq ticker does not represent an independently listed investment opportunity. The principal commercial measures for the combined franchise are therefore product revenue, clinical development progress, regulatory expansion and sustained access to treatment.
What should clinicians and industry observers watch when Servier presents its SNO 2026 data?
The most important immediate consideration will be the maturity and quality of the individual datasets presented between 12 and 15 November. For Voranigo, the extended INDIGO results will need to be interpreted in the context of prior randomisation, subsequent crossover and the statistical status of subgroup and patient-reported outcome analyses. The retrospective Grade 2 and Grade 3 cohorts will require particular attention to patient selection and differences in baseline characteristics.
For Ojemda, the four-year FIREFLY-1 presentation will provide an opportunity to examine whether previously reported treatment-free intervals and retreatment observations remain consistent with longer follow-up. The number of patients contributing to each analysis, duration of observation and reasons for restarting treatment will be important to interpretation. These findings will complement, rather than replace, the comparative evidence expected from FIREFLY-2.
A broader clinical issue is whether targeted therapy can help patients manage glioma over prolonged periods without imposing unacceptable treatment burdens. Disease control, seizure activity, functional status, growth and development, treatment duration and the need for subsequent interventions may all influence the value of therapy. Their relevance differs between paediatric and adult populations, and evidence from one medicine cannot be assumed to apply to the other.
For Servier, the conference will provide a further assessment of the clinical depth behind its expanded neuro-oncology franchise. Voranigo already has randomised evidence supporting its approved Grade 2 indication, while Ojemda has an accelerated approval supported by single-arm activity and an ongoing confirmatory programme. The next meaningful developments will be independently assessable long-term outcomes, mature retreatment evidence and the Phase 3 FIREFLY-2 results expected in 2027.
The central question is no longer simply whether Servier has assembled a substantial glioma portfolio. Its commercial and clinical progress will depend on generating evidence that defines precisely which patients benefit, how long treatment should continue and whether additional indications can meet regulatory standards. The SNO 2026 presentations will help determine how much of that evidence is already emerging and which questions must still be answered through future trials.
